Atara Biotherapeutics (ATRA) Operating Margin (2022 - 2026)
Atara Biotherapeutics (ATRA) reported Operating Margin of 652.91% for Q1 2026, down 69244.0% on a YoY basis from N/an in Q1 2025, and up 67.0% quarter-over-quarter from 1978.31% in Q4 2025.
Atara Biotherapeutics (ATRA) Operating Margin (2022 - 2026) Analysis & Trends
Atara Biotherapeutics has reported Operating Margin for 5 years, with the latest figure at 652.91% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 69244.0% year-over-year to 652.91%; the trailing twelve-month figure through Mar 2026 stood at 152.56% (down 14585.0% YoY), and the FY2025 full-year result was 5.69%, up 7040.0% from the prior year.
- Operating Margin for Q1 2026 stood at 652.91%, up from 1978.31% in the prior quarter.
- The five-year high for Operating Margin was 39.53% in Q1 2025, with the low at 34180.54% in Q4 2022.
- Historically, Operating Margin has averaged 3625.34% across 5 years, with a median of 383.56% in 2024.
- The largest YoY upside for Operating Margin was 3295081 bps in 2023 against a maximum downside of 894325 bps in 2023.
- Atara Biotherapeutics' Operating Margin stood at 34180.54% in 2022, then jumped by 96 bps to 1229.74% in 2023, then surged by 97 bps to 37.26% in 2024, then slumped by 5210 bps to 1978.31% in 2025, then jumped by 67 bps to 652.91% in 2026.
- The last three Operating Margin figures came in at 652.91% (Q1 2026), 1978.31% (Q4 2025), and 103.5% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Atara Biotherapeutics | 134.61 Mn | 126.21 Mn | 392,000.00 | -652.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -652.91% |
| Dec 31, 2025 | -1,978.31% |
| Sep 30, 2025 | -103.50% |
| Jun 30, 2025 | 18.19% |
| Mar 31, 2025 | 39.53% |
| Dec 31, 2024 | -37.26% |
| Sep 30, 2024 | -54.14% |
| Jun 30, 2024 | -63.66% |
| Mar 31, 2024 | -114.22% |
| Dec 31, 2023 | -1,229.74% |
| Sep 30, 2023 | -3,255.94% |
| Jun 30, 2023 | -9,005.55% |
| Mar 31, 2023 | -6,118.92% |
| Dec 31, 2022 | -34,180.54% |
| Jun 30, 2022 | -62.30% |
| Mar 31, 2022 | -1,206.18% |